Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
261M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
13.7M
-
Shares change
-
-2.98M
-
Total reported value, excl. options
-
$9.05M
-
Value change
-
-$2.01M
-
Put/Call ratio
-
0.73
-
Number of buys
-
11
-
Number of sells
-
-17
-
Price
-
$0.66
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) as of Q2 2023
46 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share as of Q2 2023.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.7M shares
of 261M outstanding shares and own 5.24% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.59M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (1.5M shares), Artal Group S.A. (1.44M shares), Nantahala Capital Management, LLC (1.25M shares), Laurion Capital Management LP (1.17M shares), FMR LLC (1.15M shares), FRANKLIN RESOURCES INC (811K shares), Sands Capital Ventures, LLC (725K shares), Alphabet Inc. (641K shares), and MILLENNIUM MANAGEMENT LLC (615K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.